Synergistic Effect and Long-Term Efficacy of Shilong Jiedu Formula as An Adjuvant Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma Patients

Abstract

Chemotherapy is the main treatment for diffuse large B-cell lymphoma (DLBCL), but the recurrence rate in patients after standard chemotherapy is high. Moreover, there is a significant issue of drug resistance, resulting in low remission rates when retreatment is required. Thus, there is a need to improve the overall efficacy of DLBCL treatment. In order to identify an effective approach to enhance DLBCL treatment outcomes without increasing adverse reactions, this study focused on DLBCL patients who visited our hospital from January to December 2020. The study included 53 patients who received the CHOP treatment plan in the CHOP group, and another 53 patients who received adjuvant chemotherapy with Shilong Jiedu Formula in the combination group. The treatment efficacy, quality of life, changes in molecular markers, and two-year progression-free survival were recorded for all patients, and differences between the two groups were compared. The research results reveal that patients who combined Shilong Jiedu Formula with chemotherapy achieved better remission rates compared to those who only received chemotherapy. Meanwhile, patients who combined Shilong Jiedu Formula with chemotherapy experienced higher quality of life and stronger immune function after treatment, indicating significant improvements (P < 0.05) in these aspects compared to patients who solely received chemotherapy. Importantly, adjuvant chemotherapy with Shilong Jiedu Formula also demonstrated a certain extent of improvement in the progression-free survival rate of DLBCL patients. Therefore, this study suggests that the Shilong Jiedu Formula, primarily consisting of Rehmanniae Radix Praeparata and Cuscutae Semen, holds high value as an adjuvant chemotherapy for the treatment of DLBCL.